Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adoptive cellular therapy.

D M Hoffman1, B J Gitlitz, A Belldegrun

  • 1Division of Hematology/Oncology, University of California, Los Angeles School of Medicine, Jonsson Comprehensive Cancer Center, 90095-7059, USA.

Seminars in Oncology
|April 18, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.

British journal of cancer·2017
Same author

T-cell recruitment: a tool for specific immunosuppression.

Immunology today·2014
Same author

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

European journal of cancer (Oxford, England : 1990)·2014
Same author

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

British journal of cancer·2014

Adoptive cellular therapies like lymphokine-activated killer (LAK) cells, autolymphocyte therapy (ALT), and tumor-infiltrating lymphocytes (TIL) show promise for metastatic renal cell carcinoma but haven't consistently outperformed high-dose interleukin-2 (IL-2). Future research into dendritic cells (DC) and vaccines is ongoing.

Area of Science:

  • Immunology
  • Oncology
  • Cellular Therapy

Background:

  • Metastatic renal cell carcinoma (RCC) is often resistant to chemotherapy but responds to immunotherapy.
  • Adoptive cellular therapy offers a promising avenue for enhancing anti-tumor immune responses in advanced RCC.

Purpose of the Study:

  • To review current adoptive cellular therapy strategies for metastatic renal cell carcinoma.
  • To evaluate the efficacy of established and emerging cellular immunotherapies in RCC management.

Main Methods:

  • A comprehensive literature review of peer-reviewed articles on adoptive cellular immunotherapy for RCC.
  • Analysis of studies focusing on lymphokine-activated killer (LAK) cells, autolymphocyte therapy (ALT), and tumor-infiltrating lymphocytes (TIL).

Related Experiment Videos

Main Results:

  • Established methods like LAK, ALT, and TIL have not consistently demonstrated superior efficacy compared to standard biologic response modifiers, such as high-dose bolus interleukin-2 (IL-2).
  • Ongoing trials continue to explore these and other cellular immunotherapeutic approaches.

Conclusions:

  • While past cellular therapies have advanced understanding of tumor immunobiology, they have not yet surpassed current standards of care for metastatic RCC.
  • Future directions include dendritic cell (DC) vaccines and antibody therapies, offering encouraging prospects for advanced RCC treatment.